























dARTICLE IN PRESS+ModelIABET-363; No. of Pages 8
Diabetes & Metabolism xxx (2011) xxx–xxx
Review
Vitamin D and type 2 diabetes mellitus: Where do we stand?
E. Cavalier a,∗, P. Delanaye b, J.-C. Souberbielle c, R.-P. Radermecker d
a Department of Clinical Chemistry, University of Liege, CHU Sart-Tilman, 4000 Liège, Belgium
b Department of Nephrology, Dialysis and Hypertension, University of Liege, CHU Sart-Tilman, 4000 Liège, Belgium
c Laboratoire d’explorations fonctionnelles, hôpital Necker–Enfants-Malades, 75743 Paris, France
d Department of Diabetes, Nutrition and Metabolic Disorders, University of Liege, CHU Sart-Tilman, 4000 Liège, Belgium
Received 3 January 2011; received in revised form 5 January 2011; accepted 8 January 2011
bstract
Aims. – In-vitro and observational studies have established a link between vitamin D deficiency and different type 2 diabetes outcomes (insulin
esistance, insulin secretion, glucose intolerance). Although the number of randomized controlled trials vs placebo is small, vitamin D (VTD) has
een shown to prevent increases in glucose concentration and insulin resistance, enhance insulin sensitivity and reduce systolic blood pressure in
ype 2 diabetic patients.
Methods. – In this review, we have focused on the potential mechanisms that might explain the association between VTD and type 2 diabetes
ellitus (T2DM). We have also evaluated the different epidemiological and observational studies on the topic, as well as the various interventional
tudies.
Results. – Although the in vitro studies appear to be promising in explaining the link between VTD metabolism and T2DM, the results of in vivo
tudies are conflicting. This could be related to differences in their methodological approaches.
Conclusion. – Although more studies are needed to confirm the role of VTD in the treatment of T2DM, there is nevertheless enough evidence
t this time to suggest a need to maintain 25-OH vitamin D levels in T2DM patients around 30 ng/mL over the course of a year.
2011 Elsevier Masson SAS. All rights reserved.
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ésumé
Vitamine D et diabète de type 2 : le point en 2011.
Introduction. – Des études, tant observationnelles qu’in vitro ont établi l’existence d’un lien entre une carence en vitamine D et différentes
omplications liées au diabète de type 2 (résistance à l’insuline et intolérance au glucose). Le nombre d’études randomisées en double insu contre
lacebo est malheureusement assez limité, mais il n’empêche qu’il a déjà été démontré que la vitamine D permettait de diminuer les augmentations
e la glycémie ainsi que la résistance à l’insuline, augmentait la sensibilité à l’insuline et réduisait la pression artérielle systolique chez le patient
iabétique de type 2.
Méthodes. – Dans ce travail, nous nous sommes intéressés aux mécanismes pouvant expliquer l’association vitamine D–diabète de type 2. Nous
vons également étudié quelques grandes études observationnelles et épidémiologiques et nous nous sommes concentrés sur les études randomisées
n double insu contre placebo publiées à ce jour.
Résultats. – Les études in vitro semblent assez prometteuses, mais les résultats observés dans les études in vivo sont assez conflictuels, souventPlease cite this article in press as: Cavalier E, et al. Vitamin D and type
doi:10.1016/j.diabet.2011.01.001
cause de différences de méthodologies.
Conclusion. – Nous avons encore besoin d’autres études pour clarifier le rôle de la vitamine D dans le traitement du patient diabétique de type
, mais il semble cependant évident que les concentrations plasmatiques en 25(OH)-vitamine D de ces patients devraient être maintenues aux
nvirons de 30 ng/mL tout le long de l’année.
2011 Elsevier Masson SAS. Tous droits réservés.
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. Introduction
Vitamin D (VTD) is, in fact, not a vitamin, but a prohormone.
ndeed, only a small amount of VTD can be obtained from the
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Table 1
Foods that naturally contain vitamin D.
Food Content (IU/100 g)
Halibut liver oil (D3) 200,000
Cod liver (D3) 8500
Sea eel (D3) 520
Smoked river eel (D3) 3600
Cod (D3) 50
Halibut (D3) 200
Black halibut (D3) 600
Herring (D3) 1250











Crème fraîche (D3) 40
Calf’s liver (D3) 130












































tgg (D2 and D3) 70
iquid yolk (D2 and D3) 220
iet, as it is naturally present in very few foods (Table 1). Thus,
he main source of vitamin D is sunlight-induced photochemical
onversion of 7-dehydrocholesterol after exposure of the skin to
ltraviolet B (UVB) rays (wavelength: 270–300 nm). VTD is
ound in two forms: the first, vitamin D3 (cholecalciferol), isPlease cite this article in press as: Cavalier E, et al. Vitamin D and type
doi:10.1016/j.diabet.2011.01.001
he molecule synthesized in the skin, and is also present in some
oods (mainly fatty fish from cold waters); the second, vitamin
2 (ergocalciferol), is the vitamin D found in plants (Fig. 1).
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ither vitamin D2 or D3 can also be found in many pharmaco-
ogical supplements but, whatever the source of the vitamin,
t circulates in the bloodstream bound to a carrier protein,
he vitamin D binding protein (DBP). In addition, VTD must
e hydroxylated twice to produce the most biologically active
orm–1,25(OH)2 vitamin D. The first step of hydroxylation, on
he carbon in position 25, takes place in the liver to form 25-
ydroxyvitamin D (25OHD). This step is poorly regulated: the
ore vitamin D synthesized or ingested, the greater the quantity
f 25OHD formed, although some studies have shown a neg-
tive correlation between the increase in 25OHD and baseline
lasma concentration. The half-life of 25OHD is approximately
–4 weeks. The 25OHD–DBP complex enters the proximal
enal tubule, where the second step of hydroxylation occurs on
he carbon in position 1 by the enzyme 1-alpha-hydroxylase
CYP27B1), resulting in 1,25(OH)2 vitamin D (calcitriol).
his renal stage of hydroxylation is tightly regulated, and
ainly stimulated by parathormone (PTH), hypophosphataemia
nd poor calcium intakes. The enzyme is down-regulated by
broblast growth factor-23 (FGF-23), hyperphosphataemia and
,25(OH)2 vitamin D itself. The half-life of 1,25(OH)2 vitamin
is approximately 4 h.
The best-known role of 1,25(OH)2 vitamin D is to main-
ain phosphocalcic homoeostasis by enhancing calcium and
hosphorus uptake in the gut. This endocrine function is
chieved by acting on a cytosolic receptor (the vitamin D
eceptor, or VDR), thus inducing the synthesis of different pro-
eins, such as TRPV6, calbindin 9 and NPT2b. Severe VTD
eficiency can cause rickets in children and osteomalacia in
dults.
In addition to this endocrine function, VTD plays an impor-
ant autocrine role. Indeed, most human cells express VDRs
nd possess 1-alpha-hydroxylase. The 25OHD penetrates these
ells and is hydroxylated to produce 1,25(OH)2 vitamin D,
hich remains localized to the cells and binds to the VDR.
he 1,25(OH)2 vitamin D–VDR complex penetrates into the
ucleus of the cells and is combined with the retinoic-acid
eceptor (RXR). The RXR–VDR–1,25(OH)2 vitamin D com-
lex acts on various ′vitamin D responsive elements′ (VDRE)
hat are close to the genes whose expression is thus activated
r depressed, thereby modulating the synthesis of numerous
roteins [1].
It is now believed that up to 3% of the human genome is
irectly or indirectly controlled by the VTD system [2]. In
ddition, more and more observational, experimental and also
nterventional studies have recently emerged to demonstrate
he contribution of significant VTD supplementation to dif-
erent health benefits. Of these so far, it is worth noting its
ositive effects on cancer [3], sarcopenia in the elderly [4],
ultiple sclerosis [5], hypertension [6], cardiovascular disease
7], congestive heart failure [8], lupus erythematosus [9], arthri-
is [10], type 1 diabetes [11] and various infectious diseases
12].2 diabetes mellitus: Where do we stand? Diabetes Metab (2011),
Although there is, as yet, no consensus to recommend a
arget range for serum 25OHD concentrations, the present
eport supports the suggestion that vitamin D insufficiency is
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s has already been proposed by several teams of experts
13–16].
. Association of vitamin D and type 2 diabetes mellitus:
n vitro and animal studies
Many different basic and animal studies have shown that VTD
nd calcium (Ca) are clearly involved in glycaemic homoeosta-
is, and that altered Ca and VTD concentrations play a role in the
evelopment of diabetes. The relationship between vitamin D,
a and insulin was elucidated in 1967, when Milner and Hales
17] showed that, in animals, Ca and magnesium (tightly regu-
ated by the VTD system) were essential for insulin secretion.
lso, having an inadequate VTD status may play a role in insulin
esistance [18–21]: indeed, VTD has a direct effect on insulin
ction, as it stimulates the expression of the insulin receptor and,
hus, enhances responsiveness for glucose transport [22]. Vita-
in D also has indirect (Ca-mediated) effects on insulin action:
a is tightly regulated, and intracellular Ca2+ concentrations
ust be kept within an extremely narrow range for the optimal
ction of insulin on different insulin-responsive tissues, such as
keletal muscle and fat tissue [23–25]. Changes in intracellu-
ar Ca2+ concentrations can lead to peripheral insulin resistance
ia impaired insulin signal transduction, with decreased glucose
ransporter-4 (GLUT4) activity [26]. Vitamin D also plays an
ctive role in the functional regulation of the endocrine pancreas,
s beta cells possess both VTD receptors [27] and 1-alpha-
ydroxylase [28]. Furthermore, calbindin-D28k, a Ca-binding
rotein regulated by the VTD pathway, plays a role in the mod-
lation of depolarization-stimulated insulin release (and, thus,
ontrols the rate of insulin release via regulation of intracellu-
ar Ca2+ concentration) [29], and also protects beta cells against
ytokine-mediated apoptosis and necrosis by inhibiting free rad-
cal formation [30]. Finally, different polymorphisms of the
DR have also been associated with T2DM, the metabolic syn-
rome, fasting plasma glucose and glucose intolerance [31–33].
. Vitamin D and type 2 diabetes mellitus: epidemiology
nd observational studies
In 2009, the World Health Organization (WHO) estimated
hat 220 million people worldwide had diabetes. Vitamin D defi-
iency is another global problem, as it has been estimated that
ore than one billion people worldwide are vitamin D-deficient
1].
Seasonal variations of preprandial glucose, HbA1c concen-
ration and glycaemic control have been demonstrated in T2DM
atients, being higher in winter and lower in summer [34,35].
s winter is the season when sunshine (and vitamin D produc-
ion) is reduced (with no skin vitamin D production in northern
egions), these observations could be suggesting that these sea-
onal variations are linked to seasonal variations of vitamin
.Please cite this article in press as: Cavalier E, et al. Vitamin D and type
doi:10.1016/j.diabet.2011.01.001
A cross-sectional survey of 5677 individuals in New Zealand
oncluded that serum concentrations of 25OHD were altered
n patients with newly diagnosed T2DM and impaired glucose
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among participants (with Maori and Pacific Islanders having
ower levels than Europeans) [36].
Also, the Third National Health and Nutrition Examina-
ion Survey (NHANES III) [37] showed an inverse association
etween vitamin D status and diabetes in non-Hispanic whites
nd Mexican-Americans, but not in non-Hispanic blacks, again
eflecting ethnic differences. [AU: please check ref numbers
ere; note ref 38 citation is missing in sequence. SW, editor]
ittas et al. [39] found statistically significant inverse associ-
tions between 25OHD concentrations and the prevalence of
2DM (odds ratio: 0.36, 95% CI: 0.16–0.80) on analyzing data
rom all studies reporting an association between 25OHD and
iabetes prevalence, excluding data for non-Hispanic blacks
36,50,51]. Other cross-sectional or observational studies have
een published on the topic, and their results generally–but not
lways–suggest an association between VTD status and/or Ca
ntake and T2DM risk. However, it is not reasonable to rely on
hese studies for a number of reasons, including: (1) lack of
eing adjusted for confounding factors (for example, body mass
ndex, VTD and Ca status, physical activity and outdoor activ-
ty); (2) major differences in the populations studied (ethnicity,
ean age, geographical location/latitude); and (3) wide range
f pathologies present and different outcomes (such as newly
iagnosed diabetics, glucose tolerance problems and insulin
esistance).
Nevertheless, in the Nurses’ Health Study, it appears that
omen with the highest intakes of Ca (greater than 1200 mg/day)
nd VTD (greater than 800 IU/day) had a 33% lower risk com-
ared with those who had the lowest Ca (less than 600 mg/day)
nd VTD (less than 400 IU/day) intakes. It is also worth noting
hat, in that study, the combination of Ca and VTD appeared to
e more effective than either high-dose Ca or VTD supplements
lone [38].
Finally, it should be borne in mind that, while some studies
ave shown either a positive or no effect of VTD, no negative
tudy of the topic has ever been published.
. Vitamin D and type 2 diabetes mellitus:
nterventional studies
In evidence-based medicine, the level of evidence from
nterventional studies is much more important than that of obser-
ational or cross-sectional studies. In researching the use of
ignificant VTD supplementation to achieve potential benefits
n T2DM, different interventional studies have been conducted.
owever, these studies have major differences in design and
utcomes. For this reason, the present report focuses only on
hose studies where 25OHD levels were determined. Indeed, it
s difficult to draw any conclusions from studies where the most
mportant determining factor was not evaluated. Also, only those
tudies where ‘native’ vitamin D3 or D2 was given to patients are
ncluded. In fact, it is not usually considered good practice to sup-
lement patients with 1-hydroxylated or 1.25-dihydroxylated2 diabetes mellitus: Where do we stand? Diabetes Metab (2011),
TD as the first line of treatment.
Given these criteria, only one study of all those systematically
nd well reviewed, and including meta-analysis, by Pittas et al.
n the role of vitamin D and Ca in T2DM (published in 2007)
Please cite this article in press as: Cavalier E, et al. Vitamin D and type 2 diabetes mellitus: Where do we stand? Diabetes Metab (2011),
doi:10.1016/j.diabet.2011.01.001
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Table 2
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25OHD conc: 25-hydroxyvitamin D concentration; BMI: body mass index; CPBA: chloroperbenzoic acid; HPLC: high-performance liquid chromatography; RIA:
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ould be selected [39]. However, since that time, seven other
tudies have been published, and their results are summarized
n Table 2.
In the first of these, Pittas et al. [40] showed that 700 IU/day
f D3 and 500 mg/day of Ca citrate vs placebo prevented
ncreases in plasma glucose and insulin resistance in patients
ith impaired fasting glucose. The treatment had no apparent
ffect on fasting glucose in non-glucose-impaired subjects, nor
as any effect observed on blood glucose or insulin metabolism
n non-diabetic subjects when their VTD levels were corrected
41].
In the large-scale Rosiglitazone Evaluated for Cardiac Out-
omes and Regulation of Glycaemia in Diabetes (RECORD)
rial, no prevention of the development of T2DM was observed
ith D3 at 800 IU/day alone or in combination with 1000 mg/day
f calcium carbonate (CaCO3)–doses that proved insufficient to
aise 25OHD levels to greater than 30 ng/mL [42]. However, the
% of diabetic patients in the treated group had no increased
eed for medication during the course of the study.
Sugden et al. found that, in their initial studies, 100,000 IU of
2 improved endothelial function (assessed by flow-mediated
asodilatation of the brachial artery in response to hyperaemia
nd sublingual glyceryl trinitrate) in T2DM patients [43]. These
esults are of interest because endothelial function is a powerful
urrogate marker of cardiovascular risk. However, they could
ot confirm their findings with either 100,000 or 200,000 IU
f D3 [44] (generally thought to be more effective than D2 in
aising and maintaining serum VTD levels, although this is still
subject of debate).
However, one interesting observation of the latter study
as the reduction in systolic blood pressure in the treated
roups, a change that was not observed in studies by Nag-
al et al. [45] and Jorde and Figenschau [46]. The former
ealt with obese, non-diabetic, healthy Indian men and showed
ostprandial improvement in insulin sensitivity. In the latter
tudy, patients were overtly diabetic and had stable HbA1c
evels that did not change after significant D3 supplementa-
ion (40,000 IU/week for 6 months, equivalent to a total of
,040,000 IU). No improvement in parameters of either insulin
ecretion or insulin resistance [according to the homoeosta-
is model assessment (HOMA) method] was observed in this
orwegian cohort, which was not the case of the study pub-
ished by von Hurst et al. [47] of South Asian insulin-resistant
on-diabetic women with VTD deficiency who underwent
upplementation with 4000 IU/day of D3 for 6 months (total:
30,000 IU). The mean VTD level for this cohort was 32 ng/mL
nd, when serum values reached this threshold, an improvement
n insulin resistance was observed.
. Conclusion
At present, there is no doubt that a relationship between
nsufficient VTD and Ca status and T2DM exists. However,Please cite this article in press as: Cavalier E, et al. Vitamin D and type
doi:10.1016/j.diabet.2011.01.001
he number of interventional studies, and particularly of ran-
omized controlled trials vs placebo, is limited. Moreover, the
esults observed in some of these studies have been contradic-
ory (although no study has shown worsening of the pathology). PRESS
tabolism xxx (2011) xxx–xxx
evertheless, although it may be that VTD supplementation
oes not prevent the emergence of diabetes in the healthy pop-
lation, the potential benefits of its significant supplementation
n the various parameters associated with the disease, such as
ypertension, are important. VTD supplementation may also
ave different positive consequences, such as improvement in
uscle performance that could lead to increased physical activ-
ty and weight loss and, thus, reduced insulin resistance.
Another observation worth noting from the various interven-
ional studies is the method of administration and dosages used.
ndeed, for better compliance, large yearly or monthly doses
ay be more advantageous, but may also have negative out-
omes. Indeed, when Taylor and Wise [48] treated three T2DM
atients with one intramuscular dose of 300,000 IU of D3, they
aw an increase in insulin resistance. Jorde and Figenschau [46]
ound no significant improvements in the parameters they were
tudying (which was unexpected, given the results obtained in
ther interventional studies) but, instead, saw a hypercalcaemic
vent in one subject. It should also be borne in mind that the
rotocol followed in that study was intensive (40,000 IU/week
or 6 months). Although it is generally agreed that native VTD
s not toxic at the doses used in clinical practice (there is a factor
f 1000 between therapeutic and toxic doses), a U-shape curve
ay still be seen, as was recently reported by Sanders et al. [49]
ho, on supplementing older women with yearly high doses
500,000 IU) of vitamin D3, unexpectedly found a greater risk
f falls.
Furthermore, it should be remembered that all these studies
ere performed for only a short period of time compared with a
ifetime of treatment for chronic diseases such as T2DM. Indeed,
t is not reasonable to extrapolate the conclusions of a 6-week
rial to the rest of a patient’s life.
The medical community is still awaiting more evidence, par-
icularly regarding the prevention of T2DM and improvement of
he disease with significant VTD supplementation. Nevertheless,
o far, the evidence is sufficient to suggest that T2DM patients
hould aim to maintain VTD levels greater than 30 ng/mL over
he course of a year.
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